Skip to content

Press Release Details

Seres' news, events and other information can be found throughout the pages below.

Seres Therapeutics to Present at Two Upcoming March Conferences

Mar 9, 2018 at 7:00 AM EST
PDF Version

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences:

  • The 38th Annual Cowen & Co.Health Care Conference: a corporate overview will be presented on Wednesday, March 14 at 10:40 a.m. ET in Boston, MA.
  • Oppenheimer's 28th Annual Healthcare Conference: a corporate overview will be presented on Tuesday, March 20 at 10:20 a.m. ET in New York, NY.

A live audio webcast of each presentation will be available under the “Investors and Media” section of Seres’ website. A replay of each presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent C. difficile infection. Seres’ clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis and has obtained Orphan Drug designation for pediatric Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary C. difficile infection and is developing SER-401 to enhance the efficacy of checkpoint inhibitors in patients with certain tumors. For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.

Source: Seres Therapeutics, Inc.

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Vice President, Investor Relations and Corporate Communications
ctanzi@serestherapeutics.com